[Trend in the development of new inhibitors of cyclic nucleotide metabolism and their clinical application].
Hidaka
H
H
Department of Pharmacology, Nagoya University School of Medicine.
Hagiwara
M
M
Watanabe
Y
Y
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000031:analogs & derivatives*; D000818:Animals; D000077407:Cilostazol; D000242:Cyclic AMP / Q000378:metabolism*; D006152:Cyclic GMP / Q000378:metabolism*; D003864:Depression, Chemical; D007546:Isoquinolines / Q000494:pharmacology*; D009529:Nicardipine / Q000494:pharmacology*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D013777:Tetrazoles / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology; D014748:Vinca Alkaloids / Q000494:pharmacology*
D007546:Isoquinolines; D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D014665:Vasodilator Agents; D014748:Vinca Alkaloids; C013983:vinpocetine; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D009529:Nicardipine; D000242:Cyclic AMP; D006152:Cyclic GMP; D000077407:Cilostazol; C049347:fasudil